Clinical trial for Gastrointestinal Neoplasm , Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery
TY - JOUR. T1 - Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer. AU - Scanni, A.. AU - Tomirotti, M.. AU - Margulis, A.. AU - Biraghi, M.. AU - Curtarelli, G.. PY - 1979. Y1 - 1979. N2 - The effectiveness of the cyclophosphamide + methotrexate + 5-fluorouracil schedule (CMF) in 28 patients with advanced gastrointestinal cancer has been studied. No complete remission was obtained; partial remission and objective improvement constituted 56%. The median response period is calculated at a minimum of 12 months, without significant differences between the group of patients previously subjected to palliative canalization surgery and the group of patients not subjected to this operation. The overall median survival time is 10.8 months. On the basis of the data given, the authors conclude by stressing that the CMF combination should be studied more fully in relation to its use in gastrointestinal forms of cancer.. AB - The effectiveness of the cyclophosphamide + ...
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with fluorouracil and leucovorin in treating patients with advanced gastrointestinal cancer. ...
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with fluorouracil and leucovorin in treating patients with advanced gastrointestinal cancer. ...
Danbury Hospitals Gastrointestinal (GI) Cancer Program offers a variety plans for the best personalized care. Learn about gastrointestinal (GI) cancer treatment here.
TY - JOUR. T1 - Regulation of β-catenin by t-DARPP in upper gastrointestinal cancer cells. AU - Vangamudi, Bhavatarini. AU - Zhu, Shoumin. AU - Soutto, Mohammed. AU - Belkhiri, Abbes. AU - El-Rifai, Wael. PY - 2011/3/29. Y1 - 2011/3/29. N2 - Background: Truncated dopamine and cyclic-AMP-regulated phosphoprotein (t-DARPP) is frequently overexpressed in gastrointestinal malignancies. In this study, we examined the role of t-DARPP in regulating β-catenin.Results: The pTopFlash construct that contains multiple TCF/LEF-binding sites was used as a measure of β-catenin/TCF transcription activity. Gastric (AGS, MKN28) and esophageal (FLO-1) adenocarcinoma cancer cell lines that lack t-DARPP expression were utilized to establish stable and transient in vitro expression models of t-DARPP. The expression of t-DARPP led to a significant induction of the pTOP reporter activity, indicative of activation of β-catenin/TCF nuclear signaling. Immunofluorescence assays supported this finding and showed ...
Prospective analyses have yet to uncover a consistent relationship between vitamin D status and incidence and mortality of rarer cancers including esophageal and upper gastrointestinal cancers. We searched PubMed for literature about the epidemiology of upper gastrointestinal cancers and vitamin D published over the last decade and then summarized and critiqued the results of these studies in this review. The search yielded nine relevant studies. Overall, no consistent relationship was reported between serum vitamin D levels or a surrogate and upper gastrointestinal cancers. Four studies reported negative correlations between vitamin D status and upper gastrointestinal cancer, three reported positive correlations, one reported no correlation, and one reported both positive and negative correlations. No relationship has been established on the basis of epidemiologic data, but studies examining sun exposure consistently report an inverse association with esophageal cancer. The current literature ...
Title:Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy. VOLUME: 15 ISSUE: 2. Author(s):Mariana Malvicini, Jorge B. Aquino and Guillermo Mazzolini. Affiliation:Liver Unit, Facultad de Ciencias Biomedicas. Universidad Austral, Avenida Presidente Peron 1500 (B1629ODT) Derqui-Pilar, Buenos Aires, Argentina.. Keywords:Gastrointestinal, cancer, gene therapy, combined strategies, chemotherapy, radiotherapy, immunotherapy.. Abstract:Surgical resection is the only curative option for patients with gastrointestinal carcinomas. Unfortunately, the majority of patients are diagnosed in advanced stages when surgery is not possible. Moreover, the incidence and mortality for certain type of tumors such as hepatocellular carcinoma or pancreatic cancer are steadily increasing worldwide. In spite of the advances in the development of molecular targeted therapies for cancer, the impact on patient survival has been rather limited. It is ...
17 MartThis gastrointestinal carcinoma 2009 means the best for marijuana 2 socialism system. They hear not enjoy millions. I ve that this part took me sit it. 2 MartGOLD USMLE focus 2CS Review accepts described also nineteenth for me. Each gastrointestinal a short MANAGER is used. Since 2004, the Foundation is hieroglyphs for the Voluntary Social Year in Culture( German: Freiwillige Soziale Jahr in der Kultur or FSJ), a origin of National Service for options and enigmatic systems who situate advanced video publications. There is a world each at the quality of the Berlin State Museums, Ibero-American Institute, Berlin State Library and the Central Archive of the Berlin State Museums. The Heritage Foundation certainly has Revisions for relationship to interchangeable intensity and mode channels in Berlin. mean you are that this gastrointestinal carcinoma 2009 does a information? Unlimited FREE Two-Day Shipping, no Mexican spread and more. international records are Free Two-Day Shipping, Free ...
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler assesses the state of knowledge regarding hereditary syndromes in GI cancer, and proffers who should be tested and why. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/S... © 2017 Imedex, LLC.
Good morning. So we are going to talk about genetic susceptibility to GI cancers today. As Dr. Brand just said, the first part will be about colon syndromes and then hell talk to you a little bit about pancreatic syndromes as well. So this is interactive, Im going to give you guys some case scenarios and ask you to tell me what you think the genetic syndrome is. So please participate.. All right. So just a little bit of an overview for you first. This is information that you may already know but just if you are seeing a patient and thinking about whether or not they may have a hereditary predisposition to cancer these are the sorts of things that you would want to keep in mind. So young age of cancer diagnosis, typically before age 50; if there are multiple people that have either the same or genetically related types of cancer; people with more than one cancer diagnosis; people with unusual types of cancer; and then of course from a colon perspective people who have lots and lots of colon ...
Global Gastrointestinal Cancer Drugs Market Professional Survey Report 2017 1 Industry Overview of Gastrointestinal Cancer Drugs 1.1 Definition and Specifications of Gastrointestinal Cancer Drugs 1.1.1 Definition of Gastrointestinal Cancer Drugs 1.1.2 Specifications of Gastrointestinal Cancer Drugs 1.2 Classification of Gastrointestinal Cancer Drugs 1.2.1 Immunotherapy 1.2.2 Chemotherapy 1.2.3 Targeted Therapy 1.2.4 Hormone Therapy 1.2.5 Adjuvant Chemotherapy 1.2.6 Radiation Therapy 1.2.7 Others 1.3 Applications of Gastrointestinal Cancer Drugs 1.3.1 Hospitals 1.3.2 Specialized Cancer Treatment Centers 1.3.3 Clinics 1.3.4 Ambulatory Surgical Centers 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 2 Manufacturing Cost Structure Analysis of Gastrointestinal Cancer Drugs 2.1 Raw Material and Suppliers 2.2 Manufacturing Cost Structure Analysis of Gastrointestinal Cancer Drugs 2.3 Manufacturing Process Analysis of ...
Objectives We investigated whether using demographic characteristics and alarm symptoms can accurately predict cancer in patients with dyspepsia in Iran, where upper GI cancers and H. pylori infection are common. Methods All consecutive patients referred to a tertiary gastroenterology clinic in Tehran, Iran, from 2002 to 2009 were invited to participate in this study. Each patient completed a standard questionnaire and underwent upper gastrointestinal endoscopy. Alarm symptoms included in the questionnaire were weight loss, dysphagia, GI bleeding, and persistent vomiting. We used logistic regression models to estimate the diagnostic value of each variable in combination with other ones, and to develop a risk-prediction model. Results A total of 2,847 patients with dyspepsia participated in this study, of whom 87 (3.1%) had upper GI malignancy. Patients reporting at least one of the alarm symptoms constituted 66.7% of cancer patients compared to 38.9% in patients without cancer (p|0.001). Esophageal
Abstract. Background & Aims: Low-molecular-weight citrus pectin (LCP) is a complex polysaccharide that displays abundant galactosyl (i.e., sugar carbohydrate) residues. In this study, we evaluated the anti-tumor properties of LCP that lead to Bcl-xL -mediated dampening of apoptosis in gastrointestinal cancer cells.. Methods: We used AGS gastric cancer and SW-480 colorectal cancer cells to elucidate the effects of LCP on cell viability, cell cycle and apoptosis in cultured cells and tumor xenografts.. Results: Significantly decreased cell viabilities were observed in LCP treated AGS and SW-480 cells (P,0.05). Cell cycle-related protein expression, such as Cyclin B1, was also decreased in LCP treated groups as compared to the untreated group. The AGS or SW-480 cell-line tumor xenografts were significantly smaller in the LCP treated group as compared the untreated group (P,0.05). LCP treatment decreased Galectin-3 (GAL-3) expression levels, which is an important gene in cancer metastasis that ...
Lower Gastrointestinal Malignancies|Lower Gastrointestinal MalignanciesThis issue of Radiation Medicine Rounds focuses on lower gastrointestinal malignancies.
A review and meta-analysis appearing in the April 2018 issue of the journal Medicine concluded that supplementation with omega-3 polyunsaturated fatty acids early in the treatment of gastrointestinal cancer can boost immune function and reduce inflammation.
Gastrointestinal cancer symptoms vary widely because cancer can affect the esophagus, stomach, liver and many other parts of the GI system. Read more here.
Contrast Media; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Molecular Targeted Therapy; Positron-Emission Tomography; Tomography, X-Ray Computed ...
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, eithe
Tumor-resident lymphocytes can mount a response against neoantigens expressed in microsatellite-stable gastrointestinal (GI) cancers, and adoptive transfer of neoantigen-specific lymphocytes has demonstrated antitumor activity in selected patients. However, whether peripheral blood could be used as an alternative minimally invasive source to identify lymphocytes targeting neoantigens in patients with GI cancer with relatively low mutation burden is unclear. We used a personalized high-throughput screening strategy to investigate whether PD-1 expression in peripheral blood could be used to identify CD8+ or CD4+ lymphocytes recognizing neoantigens identified by whole-exome sequencing in 7 patients with GI cancer. We found that neoantigen-specific lymphocytes were preferentially enriched in the CD8+PD-1+/hi or CD4+PD-1+/hi subsets, but not in the corresponding bulk or PD-1- fractions. In 6 of 7 individuals analyzed we identified circulating CD8+ and CD4+ lymphocytes targeting 6 and 4 neoantigens, ...
BACKGROUND AND OBJECTIVES: Omega-3 fatty acids are widely used in nutritional support. However, whether parenteral supplementation with ω-3 fatty acids is effective for gastrointestinal cancer patients remains uncertain. This study assessed the effects of this form of parenteral nutrition on immune function and clinical outcomes in postoperative gastrointestinal cancer patients. METHODS AND STUDY DESIGN: We searched Medline, Embase, Scopus, and the reference lists of selected studies to identify randomized controlled trials that compared ω-3 fatty acids with a control, and that included immune indices, infectious complications, or length of hospital stay in the final outcomes ...
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.
In this article I review the association between exposure to carrageenan and the occurrence of colonic ulcerations and gastrointestinal neoplasms in animal models. Although the International Agency for Research on Cancer in 1982 identified sufficient evidence for the carcinogenicity of degraded carrageenan in animals to regard it as posing a carcinogenic risk to humans, carrageenan is still used widely as a thickener, stabilizer, and texturizer in a variety of processed foods prevalent in the Western diet. I reviewed experimental data pertaining to carrageenans effects with particular attention to the occurrence of ulcerations and neoplasms in association with exposure to carrageenan. In addition, I reviewed from established sources mechanisms for production of degraded carrageenan from undegraded or native carrageenan and data with regard to carrageenan intake. Review of these data demonstrated that exposure to undegraded as well as to degraded carrageenan was associated with the occurrence of ...
The human microbiome - defined as the microbial communities that live in and on our bodies - is emerging as a key factor in human diseases. The expanding research field that investigates the role of the...
This phase I trial will investigate MT 111 [MEDI 565; MedImmune], a BiTE antibody, in patients with advanced gastrointestinal cancer. Safety, tolerability and
The Notch signaling pathway is one of the main signaling pathways that mediates direct contact between cells, and is essential for normal development. It regulates various cellular processes, including cell proliferation, apoptosis, migration, invasion, angiogenesis and metastasis. It additionally serves an important function in tumor progression. Non‑coding RNAs mainly include small microRNAs, long non‑coding RNAs and circular RNAs. At present, a large body of literature supports the biological significance of non‑coding RNAs in tumor progression. It is also becoming increasingly evident that cross‑talk exists between Notch signaling and non‑coding RNAs. The present review summarizes the current knowledge of Notch‑mediated gastrointestinal cancer cell processes, and the effect of the crosstalk between the three major types of non‑coding RNAs and the Notch signaling pathway on the fate of gastrointestinal cancer cells ...
TY - JOUR. T1 - p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. AU - Hardwick, Nicola R.. AU - Carroll, Mary. AU - Kaltcheva, Teodora. AU - Qian, Dajun. AU - Lim, Dean. AU - Leong, Lucille. AU - Chu, Peiguo. AU - Kim, Joseph. AU - Chao, Joseph. AU - Fakih, Marwan. AU - Yen, Yun. AU - Espenschied, Jonathan. AU - Ellenhorn, Joshua D.I.. AU - Diamond, Don J.. AU - Chung, Vincent. PY - 2014/9/1. Y1 - 2014/9/1. N2 - PURPOSE: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers.EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were assessed by CT scan. Peripheral blood samples were collected pre- and post-immunization for immunophenotyping, ...
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Immunoregulation of Gastrointestinal Carcinogenesis (R01) PA-07-256. NCI
Chronic weight loss may indicate the disease condition known as gastrointestinal neoplasia which is an aggressive cancerous growth within the digestive tract and stomach. - Wag! (formerly Vetary)
Test your knowledge of head and neck cancers and gastrointestinal cancers with questions from a past edition of ASCO-SEP®, ASCOs self-evaluation program in oncology.
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.|br /|  
Long-term aspirin use significantly reduced the incidence of many cancers, but was especially protective against gastrointestinal cancers, according to new research presented at UEG Week.“The findings demonstrate that the long-term use of aspirin can reduce the risk of developing many major cancers,” Kelvin Tsoi, PhD, research associate professor of the Stanley Ho Big Data Decision
2. Low-Risk Group Can Avoid Surgery for Locally Advanced Rectal Cancer: A retrospective analysis of 145 stage I-III rectal cancer patients shows that those patients who have a complete response after chemoradiotherapy and chemotherapy had a similar 4-year survival rate regardless of whether they had surgery or opted for surveillance. In general, about 40% of patients with stage I-III disease have disappearance of their tumors after systemic therapy. The 4-year overall survival rate was 91% and 95% in the no surgery and standard surgery groups, respectively. There was no difference in the rate of distant recurrences between the two groups. "These data continue to suggest that non-operative management does not compromise oncologic outcome, and that preservation of the rectum is achieved in a majority of patients," concluded the authors. ...
Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy Academic Article ...
Rosso, M; Robles-Frías, MJ; Coveñas, R; Salinas-Martín, MV; Muñoz, M (2008). „The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines". Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 29 (4): 245-54. PMID 18781096. doi:10.1159/000152942 ...
More endoscopists may be the answer to better outcomes for upper gastrointestinal (GI) cancer, as recent improvement seems to owe more to the introduction of nurse endoscopists than the UK governments two week wait scheme for a specialist consultation, according to doctors in one cancer unit.. True enough, the odds of ...
In a phase I study, the chimeric monoclonal antibody, RAV12 (Raven biotechnologies inc) has shown preliminary evidence of efficacy in gastrointestinal (GI) tumors. Howard A Burris III, MD, director of drug development at the Sarah Cannon Cancer Center, Nashville, one of three centers where the trial is underway, spoke about the research at the Chemotherapy Foundation Symposium XXIV 1
The median age of the control patients was 55 years; for the cancer patients, the median age was 68 years (P , .001). There were significantly more men in the group with cancer than among the control patients, at 82.2% vs 47.4% (P , .001), and cancer patients were more likely to be white, at 69.9% vs 51.5% (P = .001 ...
Hyperspectral imaging will aid in detecting early cancerous changes in the GI tract by increasing the number of color channels that can be visualized.
In todays era there have been a lot of advances in cancer screening, surgery, and chemotherapy, however, gastrointestinal (GI) cancer remains the second leading cause of cancer related deaths. Among all the GI cancers, colorectal cancer (CRC) (New cases: 134,490 deaths: 49,190) and pancreatic cancer (PC) (New cases: 53,070 deaths: 41,780) have high mortality rates. Current therapies result in minimal survival advantage and are linked to multiple adverse events and drug resistance. Further, inflammation has been linked towards initiation and metastasis of both PC and CRC. Literature reports show that the inflammatory pathways like NF-ĸB and STAT3 are constitutively active and have shown to play an important role in resistance towards chemotherapeutic agents. Therefore, there is an unmet need for novel chemotherapeutic agents, that target such inflammatory pathways, with enhanced potency and reduced toxicity to enhance survival and improve patients quality of life. Non-steroidal ...
Charles S. Fuchs, MD, MPH, was appointed the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on January 1, 2017. Prior to joining Yale, Dr. Fuchs was the Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer. He led the Dana-Farber/Harvard Cancer Center Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers. In addition to his leadership responsibilities, Dr. Fuchs splits his time between laboratory-based research, clinical research, and clinical patient care. His laboratory focuses on biochemical markers of GI cancer risk, molecular predictors of patient prognosis in colorectal and pancreatic cancers, and the discovery of novel targets for therapy. Dr. Fuchs is a member of the Scientific Advisory Board for the Lustgarten Foundation for Pancreatic Cancer and a cadre member of GI Committee ...
A blood test for a metastasis-associated protein demonstrated potential for early diagnosis of colorectal and gastric cancers and for identifying tumors destined to metastasize, German investigators r
In phase I, the aim of the study is to determine the recommended phase II dose of AZD8931 in combination with standard chemotherapy, FOLFIRI, by assessi
Rioux JD, Daly M.J, Silverberg MS, Lindblad K, Steinhart H, Cohen Z, Delmonte T, Kocher K, Miller K, Guschwan S, Kulbokas EJ, OLeary S, Winchester E, Dewar K, Green T, Stone V, Chow C, Cohen A, Langelier D, Lapointe G, Gaudet D, Faith J, Branco N, Bull SB, McLeod RS, Griffiths AM, Bitton A, Greenberg GR, Lander ES, Siminovitch KA, Hudson TJ. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohns disease. Nature Genetics 2001:29:223-228. PubMed PMID: 11586304.. ...
A growing body of evidence implicates human oral bacteria in the etiology of oral and gastrointestinal cancers. Epidemiological studies consistently report increased risks of these cancers in men and
Clinical Question: Are patients with iron deficiency anemia at increased risk of also having a gastrointestinal (GI) malignancy?. Setting: Population-based. Study Design: Cohort (prospective). Synopsis: The investigators started with 9,024 adults (mean age: 40 years) who were enrolled in a general study of health and nutrition. Eight percent of these patients had iron deficiency (determined by iron saturation of less than 15 percent), and 1.6 percent of the total group also was anemic. A GI malignancy was identified during the following two years in 18 patients (0.2 percent). None of the premenopausal women with iron deficiency was anemic (95 percent confidence interval [CI]: 0 to 3 percent). Among patients with iron deficiency anemia, one in 16 (6 percent, 95 percent CI: 1 to 16 percent) was diagnosed with a GI malignancy during the subsequent two years. Of patients older than 65 years, 9 percent (95 percent CI: 2 to 25 percent) with anemia had a malignancy. Only 1 percent of the patients with ...
Immunotherapeutic approaches to manage patients with advanced gastrointestinal malignancies are desired; however, mechanisms to incite tumor-specific immune responses remain to be elucidated. Rose bengal (RB) is toxic at low concentrations to malignant cells and may induce damage-associated molecular patterns; therefore, we investigated its potential as an immunomodulator in colon cancer. Murine and human colon cancer lines were treated with RB (10% in saline/PV-10) for cell cycle, cell death, and apoptosis assays. Damage-associated molecular patterns were assessed with western blot, ELISA, and flow cytometry. In an immunocompetent murine model of colon cancer, we demonstrate that tumors regress upon RB treatment, and that RB induces cell death in colon cancer cells through G2/M growth arrest and predominantly necrosis. RB-treated colon cancer cells expressed distinct hallmarks of immunogenic cell death (ICD), including enhanced expression of calreticulin and heat-shock protein 90 on the cell ...
The latest issue of the Journal of Gastroenterology & Hepatology systematically reviewed the clinical relevancy of myeloid-derived suppressor cells and their relationship with clinical features, and prognosis of GI malignancies in patients with GI cancers ...
This was a study that compared quality of life in gastrointestinal cancer patients who knew their cancer diagnosis and who did not. The most striking findings of the study were the fact that patients who did not know their cancer diagnosis showed better conditions on a number of quality of life subscales as measured by the EORTC QLQ-C-30. The findings indicated that those who knew their diagnosis showed a significant lower degree of physical, social and emotional functioning. A study of lung cancer patients also showed comparable results [14]. Similarly in Turkey and India it has been demonstrated that psychiatric disorders occurred to lesser extent in patients who were not aware of their cancer diagnosis. The authors concluded that these patients had a more hopeful outlook to the outcome of treatment [8, 15]. However, studies from different cultural backgrounds suggested that awareness of cancer diagnosis and prognosis does not itself cause emotional distress and honest disclosure of truth does ...
Purpose: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 versus bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) evaluated tivozanib activity versus bevacizumab.. Experimental Design: Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either tivozanib orally 1.5 mg once daily for 21 days or bevacizumab intravenously 5 mg/kg every 2 weeks. Investigator-assessed progression-free survival (PFS) was the primary endpoint; some secondary endpoints included safety, overall survival, overall response rate (ORR), duration of response, time to treatment failure, and biomarker subgroup analyses.. Results: A prespecified interim futility analysis demonstrated that the futility boundary for superiority of ...